TCM Biotech International Corp. (4169.TW)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TWD m | 737 | 702 | 802 | 970 | 667 | 685 | 685 | 700 |
| Operating profit | TWD m | 19 | 19 | ||||||
| Net profit | TWD m | 26 | 2 | 18 | 19 | 21 | 19 | 19 | 53 |
| EPS reported | TWD | 0.32 | 0.32 | ||||||
| Operating cashflow per share | TWD | 0.66 | 0.66 | ||||||
| Capex per share | TWD | 0.04 | 0.04 | ||||||
| FCF per share | TWD | 0.62 | 0.62 | ||||||
| Free cash flow | TWD m | 37 | 37 | ||||||
| Net debt | TWD m | -507 | -502 | ||||||
| Book value equity | TWD m | 1,055 | 1,055 | ||||||
| Book value per share | TWD | 17.87 | 17.87 | ||||||
| Number of shares | m | 59.07 | 59.07 | ||||||
| DPS (TTM paid) | TWD | 0.35 | 0.32 |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 535.94 | - | ||||||
| P/B LTM | x | 9.60 | 9.60 | ||||||
| P/S LTM | x | 14.77 | 14.77 | ||||||
| P/FCF LTM | x | 277.43 | 277.43 | ||||||
| EV/EBITDA LTM | x | 235.29 | 235.29 | ||||||
| EV/Sales LTM | x | 14.48 | 14.29 | ||||||
| Earnings Yield LTM | % | +0.19% | +0.22% | ||||||
| FCF Yield | % | +0.36% | +0.36% | ||||||
| Quality | |||||||||
| ROE | % | +1.82% | +1.82% | ||||||
| ROIC | % | +1.45% | +1.45% | ||||||
| Operating margin | % | +2.72% | +2.72% | ||||||
| Gross margin | % | +43.28% | +43.28% | ||||||
| FCF/Sales | % | +5.32% | +5.32% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -11.11% | -11.11% | ||||||
| Sales Growth YoY | % | +2.84% | +2.84% | ||||||
| Net Income Growth YoY | % | -8.76% | -8.76% | ||||||
| FCF Growth | % | -77.05% | -77.05% | ||||||
| Operating Profit Growth | % | +86.45% | +86.45% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.20% | +0.21% | ||||||
| Dividend Growth | % | +22.81% | +12.28% | ||||||
| Payout Ratio | % | +109.34% | +1.08% | ||||||
| FCF/Debt | x | 0.85 | 0.85 | ||||||
| Net Debt/EBITDA | x | -4.79 | -4.79 | ||||||
| EBIT/Net interest | x | 21.59 | 21.59 | ||||||
| Net debt/market cap | % | +0.37% | +0.38% | ||||||
| Net debt/Equity | x | -0.48 | -0.48 | ||||||
| Gross debt/equity | x | 0.04 | 0.04 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabetic. It also provides medical detection platform for breast cancer recurrent risk detection and postoperative detection platform for liver cancer, as well as philips non-invasive positive pressure ventilation and accessories. TCM Biotech International Corp. was founded in 1998 and is headquartered in New Taipei City, Taiwan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
TCM Biotech International Corp. (4169.TW)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabetic. It also provides medical detection platform for breast cancer recurrent risk detection and postoperative detection platform for liver cancer, as well as philips non-invasive positive pressure ventilation and accessories. TCM Biotech International Corp. was founded in 1998 and is headquartered in New Taipei City, Taiwan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free